Annovis Bio ( (ANVS) ) has provided an announcement.
Annovis Bio, Inc., a company focused on neurodegenerative diseases, has announced the filing of three new patents for combination therapies using its leading drug, buntanetap, with Trulicity and Viagra. The preclinical studies show that these combinations significantly enhance cognitive functions, potentially offering groundbreaking treatments for Alzheimer’s and Parkinson’s diseases. With buntanetap having completed Phase 3 trials, and the other drugs already FDA-approved, Annovis is poised to start Phase 3 human trials, marking a significant step forward in the fight against neurodegenerative disorders.
For an in-depth examination of ANVS stock, go to TipRanks’ Stock Analysis page.
